The antibody detects endogenous level of total NFkB-p100/p52 protein.
Aufreinigung
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography usingepitope-specific immunogen.
Immunogen
Peptide sequence around AA 864-868 (E-D-S-A-Y) derived from Human NFkB-p100, p52. Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates.
Western blotting: 1:500-1:1000 Immunohistochemistry: 1:50-1:100 Immunofluorescence: 1:100-1:200
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
Phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store at -20 °C for long term preservation (recommended). Store at 4 °C for short term use.
Target
NFKB2
(Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells 2 (NFKB2))
Andere Bezeichnung
NFkappaB-p100/p52
Hintergrund
NFKB has been detected in numerous cell types that express cytokines, chemokines, growth factors, cell adhesion molecules, and some acute phase proteins in health and in various disease states. NFKB is activated by a wide variety of stimuli such as cytokines, oxidant-free radicals, inhaled particles, ultraviolet irradiation, and bacterial or viral products. Inappropriate activation of NF-kappa-B has been linked to inflammatory events associated with autoimmune arthritis, asthma, septic shock, lung fibrosis, glomerulonephritis, atherosclerosis, and AIDS. In contrast, complete and persistent inhibition of NF-kappa-B has been linked directly to apoptosis, inappropriate immune cell development, and delayed cell growth.